Dr. Explains Peptide Stacks Used for Muscle Growth

Overview

This video discusses peptide stacks for muscle growth, framing peptides as biological “amplifiers” rather than magic cures. The wellness angle is mainly centered on risk awareness and informed decision-making, not a step-by-step fitness protocol.

---

Core mechanism: Growth hormone → IGF-1

• Growth hormone (GH) is released in pulses by the pituitary gland.
• Each GH pulse signals the liver to produce IGF-1, which supports:
  • muscle building
  • tissue repair
  • strength increases
• Peptides are described as a way to “wake up” or increase activation of this pathway—not to replace natural GH production.

Key idea: peptides are positioned as amplifiers of an existing biological signaling chain.

---

“Good, better, advanced” peptide stacking logic

1) Beginner / “cleaner” approach

• Use growth-hormone-releasing hormone (GHRH) peptides to influence GH pulses, such as:
  • sermorelin
  • CJC-1295 variants
  • tesamorelin

2) Synergy strategy (common bodybuilding pairing)

• Pair a GH-releasing peptide with an amplifier peptide—commonly ipamorelin.
• The claim is that more pulse frequency/amplitude may produce more signal to drive gains.

3) Advanced / higher-risk approach

• Instead of relying on the GH pathway, use peptides that act more directly, such as:
  • IGF-LR3
• Or use peptides described as disrupting growth limits, such as:
  • follistatin / “falstatin”

---

Peptide categories discussed

Growth hormone releasing peptides (“wake up” the pituitary)

• Sermorelin
  • Shortest half-life; described as mimicking natural GH pulses
  • Noted for sleep effects
  • Framed as milder and safer/prescribable
• CJC-1295 (no DAC)
  • Longer half-life (about ~30 minutes mentioned)
  • Intended to resist breakdown (via DPP4)
• CJC-1295 (with DAC)
  • Very long activity described as constant/non-pulsatile GH release
  • Characterized as a 6–8 day style effect
• Tesamorelin
  • Stable; produces GH elevation for up to about ~24 hours
  • FDA-approved for HIV-associated lipodystrophy (used for fat reduction)
  • Described as widely used for visceral fat

Growth hormone “amplifier” peptides

• Ipamorelin
  • Positioned as a preferred amplifier
  • Described as increasing GH pulse “volume/amplitude” without raising cortisol and prolactin
  • Contrasted with other GHRPs that may be “less clean”
• Other GHRPs (examples: GHRP-2, GHRP-6, hexarelin)
  • Similar concept, but described as potentially increasing:
    • cortisol
    • prolactin
    • hunger

Higher-risk / more advanced peptides

• IGF-LR3
  • Described as a more stable, synthetic version of IGF-1
  • Framed as acting directly on tissues, bypassing much of the GH pathway
• Follistatin / “falstatin”
  • Described as a myostatin “break”
  • Characterized as removing a limiter on muscle growth

---

Risk management / safety warnings (main wellness emphasis)

• Not medical advice / not a protocol
  • The speaker explicitly states they are not giving instructions to use peptides.
• Human data varies widely by peptide
  • More human data / approval history: sermorelin, CJC-1295, tesamorelin, ipamorelin, and many GHRPs
  • Less human data: IGF-LR3 and follistatin, described as riskier/less safe

Specific risks mentioned

• Tesamorelin
  • Possible water retention
  • Joint stiffness/pain
  • Insulin resistance at high doses
  • Possible carpal tunnel at high doses
• IGF-LR3
  • Potential lower blood sugar
  • Possible increased insulin resistance
  • Anxiety
  • Possible visceral organ growth
  • Mentioned appearance effect: a “turtle shell” look in very muscular people (as described)
• Follistatin
  • Dosing can be inconsistent
  • Larger muscle size may not always translate to strength gains

Cancer warning (strong guidance)

• If someone has active cancer/tumors or is prone to them, the speaker urges a complete stop of anything that stimulates growth-hormone-related pathways.

---

Presenters / sources

• Presenter: Dr. Ashley Frzy

  • Direct primary care clinic in Mesa, Arizona
  • Described as speaking “on the internet”

• Sources mentioned (not necessarily credited as independent research in the subtitles):

  • FDA approval status referenced for tesamorelin and sermorelin
  • DPP4 (peptide breakdown) and general GH/IGF-1 biology used as background context (no specific studies cited in the subtitles)